Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.53 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL37664 | 0.90 | HTR2A (0.62) | HTR2ATSHRIDO1RAB9AAKR1C3 | |
| SCHEMBL11199226 | 0.86 | HTR2A (0.56) | HTR2AIDO1RAB9AAKR1C3HTT | |
| SCHEMBL11000854 | 0.86 | HTR2A (0.53) | HTR2AIDO1RAB9AAKR1C3HTT | |
| SCHEMBL26397649 | 0.86 | HTR2A (0.53) | HTR2AIDO1RAB9AAKR1C3HTT | |
| SCHEMBL10732801 | 0.85 | HTR2A (0.55) | HTR2ATSHRIDO1RAB9AAKR1C3 | |
| SCHEMBL6645015 | 0.84 | RAB9A (0.61) | HTR2AIDO1RAB9AAKR1C3HTT | |
| SCHEMBL9472819 | 0.84 | HTR2A (0.51) | HTR2AIDO1RAB9AAKR1C3HTT | |
| SCHEMBL11204688 | 0.84 | HTR2A (0.57) | HTR2AIDO1RAB9AHTTALDH1A1 | |
| SCHEMBL4725847 | 0.83 | HTR2A (0.59) | HTR2ATSHRIDO1RAB9AAKR1C3 | |
| SCHEMBL1029307 | 0.83 | HTR2A (0.59) | HTR2ATSHRIDO1RAB9AAKR1C3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6825187-B2 | CARBAPENEM DERIVATIVES SUBSTITUTED AT THE 2-POSITION WITH A SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP; USE AGAINST ANTIBIOTIC RESISTANT STAPHYLOCOCCUS AUREUS AND PSEUDOMONAS AERUGINOSA, ENTEROCOCCI AND INFLUENZA VIRUS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-11-30 | — | — | US | disclosed |
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | MEIJI SEIKA KAISHA, LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1251134-A1 | NOVEL CARBAPENEM DERIVATIVES OF QUATERNARY SALT TYPE | MEIJI SEIKA KAISHA LTD. (JP) | 2002-10-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022881-A1 | Novel carbapenem derivatives of quarternary salt type | DHPS, HDHD5, RRP15 | HTR2A 4166/4885TSHR 4206/4885IDO1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.